ETNB - NASDAQ
89bio, Inc.
$14.84
+0.0000%89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
At a Glance
Live Snapshot89bio, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
89bio, Inc. Cash Flow Statement
ETNB • NASDAQ
| 89bio, Inc. Cash Flow Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-367.1M | -142.2M | -102M | -90.1M | -49.5M | -57.4M | -16.2M | |
-9.1M | 50K | 65K | 79K | 60K | 17K | 6K | |
0.0 | 127K | 0.0 | -150K | -69K | 20K | -20K | |
20.6M | 16.1M | 10.4M | 8.7M | 3.8M | 389K | 108K | |
2.3M | -3.9M | -41K | 1.5M | 498K | 30.6M | 979K | |
(0.0) | (0.0) | (0.0) | (0.0) | (142K) | (106K) | (0.0) | |
-14.5M | 657K | 10.6M | 3.3M | -1M | 937K | 2.6M | |
-367.8M | -129.2M | -81.1M | -76.8M | -46.2M | -25.5M | -12.5M | |
INVESTING ACTIVITIES | |||||||
-15K | -4K | -7K | -63K | -126K | -139K | -39K | |
(0.0) | (0.0) | (33.9K) | -7.2K | (106.7K) | (0.0) | (0.0) | |
-376.1M | -341.1M | -152.7M | -141.2M | -118.9M | (0.0) | (0.0) | |
335.2M | 218.1M | 118.8M | 148.4M | 12.2M | 0.0 | 0.0 | |
0.0 | 0.0 | -33.9K | 7.2K | -106.7K | 0.0 | 0.0 | |
-40.9M | -123M | -33.9M | (7.2M) | -106.8M | -139K | -39K | |
FINANCING ACTIVITIES | |||||||
157.6M | 496.6M | 117M | 3.8M | 157.7M | 87.7M | 0.0 | |
9.3M | 3M | 0.0 | 20M | 0.0 | 0.0 | 100K | |
(0.0) | (268K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
51.7M | 13.6M | 834K | 144K | 244K | 0.0 | 0.0 | |
218.6M | 513.1M | 117.8M | 23.9M | 157.9M | 107.7M | 23.8M | |
CASH FLOW SUMMARY | |||||||
-190.1M | 260.9M | 2.8M | -45.8M | 4.8M | 82.1M | 11.3M | |
316.2M | 55.3M | 52.5M | 98.2M | 93.4M | 11.3M | 0.0 | |
126.1M | 316.2M | 55.3M | 52.5M | 98.2M | 93.4M | 11.3M | |
-367.8M | -129.2M | -81.1M | -76.8M | -46.4M | -25.6M | -12.5M |
SEC Filings
ETNB - Filing history and reports
No SEC filings available for ETNB
Related Guides
Continue your ETNB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.